Dyne Therapeutics, Inc.
DYN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818794
In the last 90 days, Dyne Therapeutics, Inc. insiders filed 1 open-market purchase and 8 sales; 247 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $3.36B
- Insider buysLast 90 days, $40.0K in total
- 1
- Insider sellsLast 90 days, $65.7M in total
- 8
- 13F holdersQ2 2026, +20 vs. previous quarter
- 247
- 13F valueReported value at the end of Q2 2026
- $4.23B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$446.2M
- No comparable prior period
- Free cash flow, FY2025
- -$405.1M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 24.4M
- Shares sold short
- Change
- −1.09M
- −4.3% vs. previous
- Days to cover
- 10.81
- At average daily volume
Superinvestors holding DYN, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding DYN at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Dyne Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 2026 (view filing)4:15 PM ET | Oct 2 | 4 days | Posner Brian SDirector | PPurchase | +2.50K | $16.00 | +$40.0K | +10.2%27.0K after | |
| Sep 8, 2026 (view filing)4:15 PM ET | Sep 4-8 | 4 days | Friedl-Naderer JohannaChief Commercial Officer | SSale | −1.08K | $23.42 | −$25.4K | −0.7%152.9K after | 2 lots10b5-1 |
| Sep 8, 2026 (view filing)4:14 PM ET | Sep 4-8 | 4 days | Kerr DouglasChief Medical Officer | SSale | −5.04K | $22.95 | −$115.5K | −3.0%162.6K after | 2 lots10b5-1 |
| Sep 8, 2026 (view filing)4:13 PM ET | Sep 8 | Same day | Cox JohnCEO & President | SSale | −5.66K | $18.88 | −$106.8K | −1.6%357.5K after | 10b5-1 |
| Aug 17, 2026 (view filing)5:30 PM ET | Aug 13-14 | 4 days | Rhodes Jason PDirector | SSale | −2.59M | $25.20 | −$65.2M | −85.8%428.9K after | 6 lots10b5-1 |
| Aug 17, 2026 (view filing)4:08 PM ET | Aug 13 | 4 days | Friedl-Naderer JohannaChief Commercial Officer | SSale | −226 | $26.28 | −$5.94K | −0.1%154.0K after | 10b5-1 |
| Aug 17, 2026 (view filing)4:08 PM ET | Aug 13 | 4 days | Kerr DouglasChief Medical Officer | SSale | −1.56K | $26.28 | −$40.9K | −0.9%167.6K after | 10b5-1 |
| Aug 17, 2026 (view filing)4:07 PM ET | Aug 13 | 4 days | Cox JohnCEO & President | SSale | −4.99K | $26.28 | −$131.0K | −1.4%363.2K after | 10b5-1 |
| Aug 17, 2026 (view filing)4:06 PM ET | Aug 13 | 4 days | Lucera ErickChief Financial Officer | SSale | −1.80K | $26.28 | −$47.2K | −1.5%119.8K after | 10b5-1 |
| Jul 29, 2026 (view filing)4:15 PM ET | Jul 27 | 2 days | Kersten DirkDirector | SSale | −261.5K | $25.51 | −$6.67M | −6.8%3.59M after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 247 holdersThe largest institutional positions in Dyne Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30,912,287 | $686.6M | 0.45% | +126,486+0.4% | Added |
| BlackRock, Inc. | 12,404,330 | $275.5M | 0.00% | +704,460+6.0% | Added |
| Jupiter Topco LLC | 11,997,738 | $266.6M | 0.11% | +11,997,738 | New |
| FMR LLC | 11,207,000 | $248.9M | 0.01% | +2,298,020+25.8% | Added |
| State Street Corp | 7,458,263 | $165.6M | 0.00% | +804,517+12.1% | Added |
| Orbis Allan Gray Ltd | 7,006,542 | $155.6M | 0.53% | +244,311+3.6% | Added |
| Atlas Venture Life Science Advisors, LLC | 6,800,099 | $151.0M | 17.14% | −2,330,366−25.5% | Reduced |
| Vanguard Capital Management LLC | 6,310,969 | $140.2M | 0.00% | −94,100−1.5% | Reduced |
| TCG Crossover Management, LLC | 4,615,144 | $102.5M | 2.46% | 00.0% | Unchanged |
| Vanguard Portfolio Management LLC | 4,048,428 | $89.9M | 0.00% | −113,613−2.7% | Reduced |
Holders of 5% or more of DYN
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Dyne Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 18.70%30.8M shares | +2.50 ppfrom 16.20% | Jan 8, 20263 filings | May 15, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 7.30%12.0M shares | −1.00 ppfrom 8.30% | Nov 14, 20248 filings | Aug 13, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.00%11.5M shares | +1.20 ppfrom 5.80% | Oct 22, 20244 filings | Jul 28, 2026 | SEC |
| FMR LLC | 13G/A | 6.80%11.2M shares | +1.40 ppfrom 5.40% | Nov 12, 20245 filings | Aug 6, 2026 | SEC |